Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR.
Chemokine receptor 7 (CCR7) upregulation, which mediates immune cell survival and migration to lymph nodes, has recently been associated with nodal metastasis of squamous cell carcinoma of the head and neck (SCCHN). However, the mechanism of CCR7 in tumor progression, its downstream signaling mediators, and interactions with other pathways contributing to metastasis of SCCHN have not been determined. We hypothesized that inflammatory chemokine-mediated signals could also promote tumor proliferation and mitogenic effects. Functional assays showed that chemotaxis and invasion of metastatic SCCHN cells were dependent on phosphoinositide-3 kinase (PI3K) and its substrate, activated phospholipase Cgamma-1. In addition, treatment of CCR7(+) metastatic SCCHN cells with CCL19 (MIP-3beta) showed rapid activation of the prosurvival, PI3K/Akt pathway. Transactivation of EGFR-mediated and mitogen-activated protein kinase signaling pathways, which can promote migration and survival in parallel, did not appear to contribute to the functional or biochemical effects of CCR7 stimulation. Thus, proinflammatory chemokine signals that mediate activation, trafficking and survival of tumor-infiltrating immune cells in the tumor microenvironment actually appear to induce signals for progression of cancer cells. The CCR7-mediated pathway in metastatic SCCHN cells functions independently of EGFR signal transduction and therefore may represent an additional target for therapeutic intervention to prevent tumor progression and metastasis.
Wang
Jun
J
Department of Otolaryngology, University of Pittsburgh School of Medicine, PA 15213, USA.
Zhang
Xin
X
Thomas
Sufi M
SM
Grandis
Jennifer R
JR
Wells
Alan
A
Chen
Zhuo Georgia
ZG
Ferris
Robert L
RL
D019870:1-Phosphatidylinositol 4-Kinase / Q000378:metabolism*; D045744:Cell Line, Tumor; D002633:Chemotaxis / Q000502:physiology; D004789:Enzyme Activation / Q000502:physiology*; D066246:ErbB Receptors / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000201:enzymology*; D006801:Humans; D015151:Immunoblotting; D047468:Immunoprecipitation; D009361:Neoplasm Invasiveness; D051966:Phospholipase C gamma; D054400:Receptors, CCR7; D019707:Receptors, Chemokine / Q000378:metabolism*; D010738:Type C Phospholipases / Q000378:metabolism
C515370:CCR7 protein, human; D054400:Receptors, CCR7; D019707:Receptors, Chemokine; D019870:1-Phosphatidylinositol 4-Kinase; D066246:ErbB Receptors; D010738:Type C Phospholipases; D051966:Phospholipase C gamma